A phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: Influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity

Oncology (Switzerland)

Volumn 82, Issue 5, 2012, Pages 290-297

  Choi, Yoon Hee ^a   Kim, Tae Won ^a   Kim, Kyu Pyo ^a   Lee, Sung Sook ^a   Hong, Yong Sang ^a   Ryu, Min Hee ^a   Lee, Jae Lyun ^a   Chang, Heung Moon ^a   Ryoo, Baek Yeol ^a   Kim, Ho Sook ^b   Shin, Jae Gook ^b   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; CYP2A6; Irinotecan; Phase II study; S 1; UGT1A1

Indexed keywords

CYTOCHROME P450 2A6; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALLELE; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CORRELATION ANALYSIS; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; POLYMORPHISM, GENETIC; TEGAFUR; TREATMENT OUTCOME;

EID: 84860571934     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000337989     Document Type: Article

References (44)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Meta-analysis Group In Cancer. J Clin Oncol 1998 16 301-308.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047. (Pubitemid 30162806)
4. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R, Italian Trials in MO: Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-287. (Pubitemid 38063635)
5. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 968-973. (Pubitemid 43778988)
6. Kerr D: Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. Oncology (Williston Park, NY) 2002; 16: 12-15.
7. Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio B, Hahn S, Vaughn D, Thorn C, Whitehead AS, Haller DG, O'Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. Eur J Cancer 2004; 40: 508-514. (Pubitemid 38220766)
8. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557. (Pubitemid 26276346)
9. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000; 83: 141-145. (Pubitemid 30411708)
10. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A: Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004; 100: 2355-2361. (Pubitemid 38657882)
11. Van den Brande J, Schöffski P, Schellens JHM, Roth AD, Duffaud F, Weigang-Köhler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P: EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88: 648-653. (Pubitemid 36411437)
12. Kusaba H, Esaki T, Futami K, Tanaka S, Fujishima H, Mitsugi K, Sakai K, Ariyama H, Tanaka R, Kinugawa N, Ueki T, Mibu R, Baba E, Nakano S, Akashi K: Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. Cancer Sci 2010; 101: 2591-2595.
13. Shiozawa M, Akaike M, Sugano N, Tsuchida K, Yamamoto N, Morinaga S: A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2010; 66: 987-992.
14. Tsunoda A, Yasuda N, Nakao K, Narita K, Watanabe M, Matsui N, Kusano M: Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 2009; 77: 192-196.
15. Yoshioka T, Kato S, Gamoh M, Chiba N, Suzuki T, Sakayori N, Kato S, Shibata H, Shimodaira H, Otsuka K, Kakudo Y, Takahashi S, Ishioka C: Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 2009; 101: 1972-1977.
16. Choi YH, Kim TW, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Kang YK: A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. Cancer Chemother Pharmacol 2011; 68: 905-912.
17. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388. (Pubitemid 41103619)
18. Gagné J, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-617. (Pubitemid 36329379)
19. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854. (Pubitemid 28096082)
20. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ: Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes. Pharmacogenet Genomics 2005; 15: 295-301. (Pubitemid 40676550)
21. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ: UGT1A1 * 28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47. (Pubitemid 34982202)
22. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ, Dutch Colorectal Cancer Group study: UGT1A1 * 28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99: 275-282.
23. Liu C, Chen P, Chiou T, Liu J, Lin J, Lin T, Chen W, Jiang J, Wang H, Wang W: UGT1A1 * 28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112: 1932-1940. (Pubitemid 351574068)
24. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515. (Pubitemid 38746601)
25. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wens ke C, Medgyesy D, Dwivedy S, Russo M, Pazdur R: Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003; 9: 134-142. (Pubitemid 36109725)
26. Goh BC SRA: Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping. J Clin Oncol 2008; 26: Abstract 2507.
27. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T: Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72-78. (Pubitemid 32108674)
28. Ariyoshi N, Sawamura Y, Kamataki T: A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun 2001; 281: 810-814. (Pubitemid 32917874)
29. Oscarson M: Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29: 91-95. (Pubitemid 32112920)
30. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon J, Yokoi T: Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6 * 9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69-76. (Pubitemid 36776178)
31. Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K: The CYP2A6 * 4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther 2008; 83: 589-594. (Pubitemid 351417063)
32. Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y: CYP2A6 and the plasma level of 5-chloro-2,4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1 2008; 99: 1049-1054. (Pubitemid 351997611)
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
34. Yea SS, Lee SS, Kim WY, Liu KH, Kim H, Shon JH, Cha IJ, Shin JG: Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 2008; 30: 23-34. (Pubitemid 351161095)
35. Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW: Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011; 104: 605-612.
36. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1 * 6 and * 28. Pharmacogenet Genomics 2007; 17: 497-504. (Pubitemid 46905216)
37. Marcuello E, Paez D, Pare L, Salazar J, Sebio A, del Rio E, Baiget M: A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 2011; 105: 53-57.
38. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875. (Pubitemid 46223991)
39. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676. (Pubitemid 46797946)
40. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786. (Pubitemid 350086481)
41. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-860.
42. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-2244.
43. Sai K, Saito Y, Sakamoto H, Shirao K, Kurose K, Saeki M, Ozawa S, Kaniwa N, Hirohashi S, Saijo N, Sawada J, Yoshida T: Importance of UDP- glucuronosyltransferase 1A1 * 6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 2008; 261: 165-171.
44. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-2465.